Seeking to achieve capital growth, this fund primarily allocates its assets to common stocks. A minimum of 80% of its portfolio is typically invested in companies deeply engaged in the biotechnology sector, encompassing those involved in the research, development, manufacturing, and distribution of biotech products and services, or firms positioned to significantly benefit from scientific and technological progress in the field. The fund's holdings include securities from both domestic and foreign issuers.